Forte Biosciences
FBRX
57 hedge funds and large institutions have $65.6M invested in Forte Biosciences in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 6 reducing their positions, and 7 closing their positions.
367% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 6
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
30% more funds holding
Funds holding: 44 → 57 (+13)
0.01% less ownership
Funds ownership: 0.1% → 0.09% (-0.01%)
22% less call options, than puts
Call options by funds: $331K | Put options by funds: $425K
27% less capital invested
Capital invested by funds: $90.3M → $65.6M (-$24.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.04M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.25M |
| 3 |
AG
Artal Group
Luxembourg
|
+$1.07M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.07M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$978K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$18.7M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$5.39M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.13M |
| 4 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$1.54M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$623K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $26K | +$27.9K | +7 | New |
|
|
SO
52
STRS Ohio
Columbus,
Ohio
| $25K | – | – | – |
|
|
AIP
53
Ameritas Investment Partners
Lincoln,
Nebraska
| $16K | +$7.98K | +2 | +100% |
|
54
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $10K | – | – | – |
|
|
AG
55
Advisor Group
Phoenix,
Arizona
| $10K | +$12K | +3 | New |
|
56
Simplex Trading
Chicago,
Illinois
| $9K | +$7.98K | +2 | New |
|
|
IP
57
Isthmus Partners
Madison,
Wisconsin
| $5K | – | – | – |
|
|
EC
58
EcoR1 Capital
San Francisco,
California
| – | -$18.7M | -4,006 | Closed |
|
|
ACP
59
Acuta Capital Partners
Redwood City,
California
| – | -$3.13M | -670 | Closed |
|
|
NIP
60
Nicholas Investment Partners
Rancho Santa Fe,
California
| – | -$623K | -133 | Closed |
|
|
AC
61
Ascend Capital
Orinda,
California
| – | -$464K | -99 | Closed |
|
|
NFA
62
Nationwide Fund Advisors
Columbus,
Ohio
| – | -$59K | -13 | Closed |
|
|
TRCT
63
Tower Research Capital (TRC)
New York
| – | -$24K | -5 | Closed |
|
64
UBS Group
Zurich,
Switzerland
| – | -$3K | -1 | Closed |
|
FBRX Hedge Fund Activity: Q4 2017 in Review
57 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q4 2017, worth a combined $65.6M — down 27% from $90.3M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new FBRX positions and 7 closed out — a net gain of 13 holders — while 28 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $3.04M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $18.7M sold.
- 57 institutional investors held Forte Biosciences (FBRX) as of Q4 2017, up from 44 in Q3 2017.
- Funds reported $65.6M of Forte Biosciences stock for Q4 2017, down 27% quarter-over-quarter.
- 20 funds opened new Forte Biosciences positions in Q4 2017 and 7 closed out, a net change of +13 holders.
- The largest Forte Biosciences buyer in Q4 2017 was BlackRock, an estimated $3.04M added.
- The largest Forte Biosciences seller in Q4 2017 was EcoR1 Capital, an estimated $18.7M sold.
Based on aggregated 13F filings for Q4 2017.